BioLineRx, Ltd.

Quick facts

Phase 2 pipeline

• BL - 1020 · Nephrology
  BL-1020 is a vasopressin V2 receptor antagonist.
• BL 1020 High Dose · Psychiatry
  BL 1020 is a dopamine D3 receptor antagonist that modulates dopaminergic signaling in the brain.
• BL-7040 · Autoimmune diseases
  BL-7040 is a small molecule that acts as a sphingosine-1-phosphate receptor 1 (S1P1) modulator.

Phase 1 pipeline

• BL-7010

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BioLineRx, Ltd. portfolio CI brief
• BioLineRx, Ltd. pipeline updates RSS